Last reviewed · How we verify
Vonoprazan triple therapy
Vonoprazan triple therapy is a Small molecule drug developed by Alexandria University. It is currently FDA-approved.
At a glance
| Generic name | Vonoprazan triple therapy |
|---|---|
| Sponsor | Alexandria University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Rescue Therapy for Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan triple therapy CI brief — competitive landscape report
- Vonoprazan triple therapy updates RSS · CI watch RSS
- Alexandria University portfolio CI
Frequently asked questions about Vonoprazan triple therapy
What is Vonoprazan triple therapy?
Vonoprazan triple therapy is a Small molecule drug developed by Alexandria University.
Who makes Vonoprazan triple therapy?
Vonoprazan triple therapy is developed and marketed by Alexandria University (see full Alexandria University pipeline at /company/alexandria-university).
What development phase is Vonoprazan triple therapy in?
Vonoprazan triple therapy is FDA-approved (marketed).
Related
- Manufacturer: Alexandria University — full pipeline
- Compare: Vonoprazan triple therapy vs similar drugs
- Pricing: Vonoprazan triple therapy cost, discount & access